Scholars Central

Review articlePublished 26 May 2025

Acute Myelogenous Leukemia: Pathogenesis, Modern Therapies, and Future Directions

Authors: Abhit Singh

Journal of Leukemia

Volume 13 · Issue 3 · Pages 1–15

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Acute Myelogenous Leukemia (AML) is an aggressive hematologic malignancy characterized by clonal proliferation of myeloid precursors with impaired differentiation. This review provides a comprehensive overview of AML etiology, molecular pathophysiology, current treatment strategies, and emerging therapies, with a focus on United States clinical practice. We detail known risk factors for AML, including antecedent hematologic disorders, genetic predispositions, environmental and iatrogenic exposures, while noting most cases are de novo without a clear cause. The complex molecular biology of AML is discussed, highlighting key cytogenetic abnormalities and mutations (FLT3, NPM1, TP53, IDH1/2, DNMT3A, etc.) that drive leukemogenesis and inform prognostic risk stratification. Standard induction chemotherapy (e.g. 7+3 cytarabine plus anthracycline) and consolidation with high-dose cytarabine or allogeneic Hematopoietic Stem Cell Transplant (HSCT) remain central to therapy for fit patients. Supportive care measures are crucial for managing cytopenias and treatment complications. We review recent therapeutic advances, including targeted small molecules (FLT3 and IDH inhibitors, BCL-2 inhibitor venetoclax) and immunotherapies (antibody-drug conjugates, bispecific T-cell engagers, CAR-T cells, checkpoint inhibitors), as well as experimental radioimmunotherapy approaches. Five-year survival outcomes are presented by age and genetic risk, underscoring the disparity between younger patients (~40%-45% survival) and older adults (<15%), and between favorable-risk (~70%) and adverse-risk (~20%-25%) disease. Ongoing clinical trials and investigational agents in the AML pipeline are reviewed, such as novel epigenetic modifiers and immune-based therapies. We also provide tables comparing therapeutic regimens, risk stratification, and survival outcomes, and include figures illustrating key molecular pathways and treatment algorithms. Through extensive literature review and up-to-date data, we aim to inform clinicians and researchers about the current state of AML management and future directions in this rapidly evolving field.

Subjects

Haematology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Leukemia.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Leukemia
  • SubjectHaematology
  • BylineArticles whose byline prints “Abhit Singh”